Benefit design duration

Certain conclusions can now be developed, based on creep-data test results First, for practical design purposes, the data accumulated for up to 100 hours of creep are of no real benefit. There is usually too much variation during this test period, which is of a relatively short duration. 

What is the minimum duration of maintenance treannent providing clinical benefit, e.g. to prevent relapse or recurrence of a depressive episode (see p. 277f. ReimhMT et al.y 1998) The design addressing this issue is similar to the previous one but with different durations of active-maintenance treatment arms compared with a full-time placebo treatment arm. 

The first generation of cholinomimetics, such as arecoline, bethanecol and pilocarpine, were not designed for the treatment of AD and the results of the early clinical trials were consistently disappointing. In addition to their poor bioavailability and short duration of action, any therapeutic benefits were limited by their cholinergic side effects. The second generation of muscarinic... 

Four hundred adults presenting with acute watery diarrhea were entered into a randomized, placebo controlled, double blind clinical trial of berberine, tetracycline, and tetracycline + berberine to study the antisecretory and vibriostatic effects of the alkaloid. Of 18S patients with cholera, those given tetracycline or tetracycline + berberine had considerably reduced volume and frequency of diarrheal stools, duration of diarrhea, and volumes of required intravenous and oral rehydration fluid. Berberine did not produce an antisecretory effect, but analysis by factorial design equations showed a reduction in diarrheal stools by one liter and a reduction in cyclic AMP concentrations in stools by 77% in the groups given berberine. Many fewer patients given tetracycline or tetracycline + berberine excreted vibrios in their stools after 24 hours in comparison with those given berberine alone. Neither tetracycline nor berberine had any benefit over placebo in 215 patients with noncholera diarrhea [219]. 

Simulation requires an enrichment of the work process model by quantitative information of different kind. Examples include the duration of certain activities or the number and type of tools allocated to a certain design task. Such information allows to investigate the time required to accomplish a part of the design process or to study the benefit of employing such tools. Such quantitative data are often hard to get with the desired accuracy in industrial practice. 

Activation of unemployment benefit recipients in the US is a concept well advanced in years. 10 Earliest discussions on the design of UI in the US focused on the issue of the insurability of unemployment (Blaustein 1993). Compensable joblessness was (and is) restricted to involuntary unavoidable unemployment (initial and continuing). The term moral hazard is insurance jargon for a situation where the insured can control the risk of exposure to the hazard insured against. UI rules were set to reduce the problem of moral hazard. UI programmes included features intended to prevent unemployment (Commons 1922). These features included definitions of involuntary unemployment, requirements for active job search, and benefit amounts and potential durations of benefits set below thresholds considered disincentives for actively seeking work. 

The discovery and development efforts that led to successful approval of boceprevir and telaprevir have produced tangible benefits to HCV patients worldwide. Meta-analyses designed to compare the efficacy and safety of boceprevir and telaprevir have been reported. Cooper and coworkers concluded that boceprevir and telaprevir appear comparable in terms of SVR, relapse, or discontinuation of therapy for patients treated under standard or response-guided therapy durations. In a separate analysis, Sitole and co-workers concluded that the triple therapies utilizing either boceprevir or telaprevir for HCV genotype 1 infection resulted in more patients reaching SVR but also in more drug-related adverse events. Additionally, this study noted that short-term treatment response... 

The design of a medicine requires clarity about its intended use in a target patient population. Commonly asked questions include What therapeutic benefit should a patient gain , How large is the patient populatimi , Do patients have unique pathophysiological or practical situations , Where in the body is the desired therapeutic target for the active substance , or What is the duration of dose administration and where is it performed (e.g. patient selfadministration at home or in-patient setting at a hospital) ... 

---